Clinical Trial: Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours

Brief Summary: The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.

Detailed Summary:
Sponsor: Uppsala University

Current Primary Outcome: Correlation between FDG-PET and tumor biology [ Time Frame: Through study completion, an average of 3 years. ]

18F-FDG-PET SUVmax correlation to Ki67 index (determined as percentage of tumor cells with positive Ki67 imunohistochemical staining).


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Uppsala University

Dates:
Date Received: April 6, 2017
Date Started: May 1, 2017
Date Completion: January 1, 2022
Last Updated: April 25, 2017
Last Verified: April 2017